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In The Lancet Psychiatry, Lai and colleagues1 describe the results of a systematic review and 
meta-analysis of the prevalence of co-occurring mental health/psychiatric conditions (CMHCs) 
in autism spectrum disorder (hereafter “autism”). Autism encompasses a group of 
neurodevelopmental conditions affecting social communication and repetitive behaviour 
patterns with wide variability in symptom severity, intellectual and language functioning, and co-
occurring problems. There is great variability both between individuals at any specific age and 
within individuals across development. Addressing this clinical heterogeneity is an important 
challenge in any study aiming to answer a question about characteristics of people with autism 
“in general”.  
In this meta-analysis, only pooled prevalence estimates and their confidence intervals 
are highlighted in the abstract and main text. Confidence intervals demonstrate the uncertainty 
around the average prevalence estimate for the average study. However, prediction intervals 
are necessary to take into account between-study variability, and therefore provide important 
information for interpretation of results.2,3 We would like to bring attention to the wide prediction 
intervals. For example, the pooled prevalence estimate for anxiety disorder diagnosis was 20% 
(95% CI=17-23), but based on the prediction interval, a new sample of individuals with autism 
can be expected to show estimates of anxiety disorder ranging between 2% and 48% 
(prediction interval for ADHD 4-63%, depression 0-33%, bipolar spectrum disorders 0-19%, 
schizophrenia spectrum disorders 0-14%, obsessive-compulsive disorder 1-21%, disruptive 
disorders 0-36%, and sleep-wake disorders 0-43%).  
The wide prediction intervals and extreme between-study variability (I2 exceeding 95%) 
make it difficult to interpret the overall prevalence estimates of CMHCs across all individuals 
with autism. Nevertheless, the article is important in highlighting the need for future work parsing 
the heterogeneity in CMHCs in autism. Focusing on well-characterized subgroups can help 
answer clinically relevant questions, such as what is the prevalence of anxiety disorders in 
school-aged males with autism and average-range intellectual functioning, or in adolescent 
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females with autism and intellectual disability? Lai and colleagues performed meta-regression 
with pre-specified potential moderators of prevalence of CMHCs, which were considered 
exploratory due to limited power. The ability to fully explore rates of CMHCs across specific 
subgroups may also be limited by poor reporting on patient characteristics. In studies regarding 
the prevalence of ADHD in autism, for example, nearly a third did not report on intellectual 
functioning. As Lai and colleagues suggest, it will be critical for future work in this area to 
provide more interpretable insights into CMHCs in autism across subgroups and within 
individuals across development. 
The primary justification for meta-analysis is explained as “Accurate ‘prior knowledge’ of 
the prevalence of CMHCs in autism provides critical background information for adequate 
mental health evaluation and service delivery.”1 However, the meta-analysis focused on the 
prevalence of clinician-assigned diagnoses of CMHCs without any criteria for assessment of 
CMHCs beyond the use of ICD/DSM criteria. As acknowledged by Lai and colleagues, the way 
CMHCs have been diagnosed in autism by different clinicians across different countries and 
health care systems during the past two decades is likely to vary widely, and undoubtedly 
contributes to the extreme between-study variability in prevalence estimates. CHMCs might not 
be systematically assessed in individuals with autism, maybe especially in those with lower 
intellectual and language functioning. For example, a diagnosis of depression may not even be 
considered in someone who cannot verbally express his/her sadness.4 Similarly, assessment 
measures of ADHD largely rely on assumptions of within-average range intelligence when 
evaluating regulation of attention, impulsivity and activity.5 Therefore, beyond the need to 
consider whether apparently inattentive or impulsive behaviours are manifestations of autism 
symptoms, clinicians must further determine whether activity and attention is affected beyond 
what would be expected for developmental level.5 The Diagnostic Manual-Intellectual Disability-
26 was developed to assist with the challenges inherent in interpreting standard diagnostic 
criteria in individuals with intellectual disability (including those with limited verbal ability). Still, 
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use of this tool, or instruments designed for assessment of CHMCs in autism, are not 
necessarily standard practice.  
The DSM-5 requires clinicians to consider and provide diagnostic specifiers of CHMCs 
and other traits with implications for prognosis and/or treatment in individuals with autism (e.g., 
intellectual functioning, language level and medical conditions). We hope that this will inspire 
more systematic assessment of CHMDs in autism. We agree fully with the authors’ conclusion 
that the available evidence implies that “mental health assessment should be an integral aspect 
of clinical care with regular screening, evaluation and treatment undertaken as part of ongoing 
support for individuals with autism.”1  
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